CytoDyn’s Chairman, CMO, and Head of Business De
Post# of 153937
(Total Views: 534)
Posted On: 09/21/2021 8:00:43 AM
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Dr. Scott Kelly, CytoDyn’s Chairman of the Board, Chief Medical Officer and Head of Business Development, will be presenting at the World Antiviral Congress 2021. The Congress will be held from November 30 – December 2, 2021, in San Diego.
Dr. Kelly will speak on Wednesday, November 30, 2021, at 2:55pm PDT about emerging approaches to antivirals, specifically focusing on leronlimab. Dr. Kelly’s segment is entitled, “Leronlimab – a platform mab CCR5 antagonist and its role in antiviral indications.”
Dr. Kelly stated, “It is an exceptional honor to be asked to present at the World Antiviral Congress and a testament to the incredible potential the medical community sees with leronlimab. The Congress brings together thought leaders and representatives of the largest pharmaceutical companies and the most prestigious academic institutions from around the world to discuss the future of antiviral therapy. I look forward to this opportunity to explain leronlimab’s applications in HIV, COVID-19, and COVID-19, Long Hauler’s syndrome and the possibilities of other antiviral indications through immunomodulation and immune restoration.”
The World Antiviral Congress 2021 agenda is available here: https://www.terrapinn.com/conference/world-an...agenda.stm.
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Dr. Scott Kelly, CytoDyn’s Chairman of the Board, Chief Medical Officer and Head of Business Development, will be presenting at the World Antiviral Congress 2021. The Congress will be held from November 30 – December 2, 2021, in San Diego.
Dr. Kelly will speak on Wednesday, November 30, 2021, at 2:55pm PDT about emerging approaches to antivirals, specifically focusing on leronlimab. Dr. Kelly’s segment is entitled, “Leronlimab – a platform mab CCR5 antagonist and its role in antiviral indications.”
Dr. Kelly stated, “It is an exceptional honor to be asked to present at the World Antiviral Congress and a testament to the incredible potential the medical community sees with leronlimab. The Congress brings together thought leaders and representatives of the largest pharmaceutical companies and the most prestigious academic institutions from around the world to discuss the future of antiviral therapy. I look forward to this opportunity to explain leronlimab’s applications in HIV, COVID-19, and COVID-19, Long Hauler’s syndrome and the possibilities of other antiviral indications through immunomodulation and immune restoration.”
The World Antiviral Congress 2021 agenda is available here: https://www.terrapinn.com/conference/world-an...agenda.stm.
(3)
(0)